Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IKN-001
- Development stage
- Preclinical
- Lead developer
- Ikaika Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
IKN-001 is a monoclonal antibody developed by Ikaika Therapeutics that targets Latent TGF-β Binding Protein 4 (LTBP4). It is designed to bind to the hinge region of LTBP4, protecting it from proteolytic cleavage by local proteases released during tissue injury. By stabilizing LTBP4, the antibody inhibits the activation of latent transforming growth factor-β (TGF-β), a potent driver of fibrosis. This mechanism aims to reduce fibrosis and promote muscle growth and regeneration in conditions such as Duchenne Muscular Dystrophy (DMD), Limb Girdle Muscular Dystrophy (LGMD), and sarcopenia, as well as other fibrotic diseases like idiopathic pulmonary fibrosis (IPF) and cancer-related fibrosis.
- Other names
- Anti-LTBP4 monoclonal antibodyAnti-LTBP-4 monoclonal antibodyAnti-LTBP 4 monoclonal antibody
02
Targets
LTBP4 (Latent-transforming growth factor beta-binding protein 4)
Beyond the preview
Go deeper on IKN-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IKN-001.